Literature DB >> 16227461

Disorders of glucose metabolism in sleep apnea.

Naresh M Punjabi1, Vsevolod Y Polotsky.   

Abstract

Sleep is a complex behavioral state that occupies one-third of the human life span. Although viewed as a passive condition, sleep is a highly active and dynamic process. The sleep-related decrease in muscle tone is associated with an increase in resistance to airflow through the upper airway. Partial or complete collapse of the airway during sleep can lead to the occurrence of apneas and hypopneas during sleep that define the syndrome of sleep apnea. Sleep apnea has become pervasive in Western society, affecting approximately 5% of adults in industrialized countries. Given the pandemic of obesity, the prevalence of Type 2 diabetes mellitus and metabolic syndrome has also increased dramatically over the last decade. Although the role of sleep apnea in cardiovascular disease is uncertain, there is a growing body of literature that implicates sleep apnea in the pathogenesis of altered glucose metabolism. Intermittent hypoxemia and sleep fragmentation in sleep apnea can trigger a cascade of pathophysiological events, including autonomic activation, alterations in neuroendocrine function, and release of potent proinflammatory mediators such as tumor necrosis factor-alpha and interleukin-6. Epidemiologic and experimental evidence linking sleep apnea and disorders of glucose metabolism is reviewed and discussed here. Although the cause-and-effect relationship remains to be determined, the available data suggest that sleep apnea is independently associated with altered glucose metabolism and may predispose to the eventual development of Type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227461     DOI: 10.1152/japplphysiol.00695.2005

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  113 in total

1.  Acute upper airway responses to hypoglossal nerve stimulation during sleep in obstructive sleep apnea.

Authors:  Alan R Schwartz; Maree Barnes; David Hillman; Atul Malhotra; Eric Kezirian; Philip L Smith; Thomas Hoegh; Daniel Parrish; Peter R Eastwood
Journal:  Am J Respir Crit Care Med       Date:  2011-12-01       Impact factor: 21.405

2.  Effect of continuous positive airway pressure therapy on glucose control.

Authors:  Salim Surani; Shyam Subramanian
Journal:  World J Diabetes       Date:  2012-04-15

3.  Good primary care is obesity medicine.

Authors:  Ingrid Kohlstadt
Journal:  MedGenMed       Date:  2007-11-26

4.  Sleep Apnea and Metabolic Dysfunction: Cause or Co-Relation?

Authors:  R Nisha Aurora; Naresh M Punjabi
Journal:  Sleep Med Clin       Date:  2007-06-01

5.  Sleep and Glucose Intolerance/Diabetes Mellitus.

Authors:  Mary Ip; Babak Mokhlesi
Journal:  Sleep Med Clin       Date:  2007

Review 6.  Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components.

Authors:  Girardin Jean-Louis; Ferdinand Zizi; Luther T Clark; Clinton D Brown; Samy I McFarlane
Journal:  J Clin Sleep Med       Date:  2008-06-15       Impact factor: 4.062

7.  SLEEP DISORDERED BREATHING AND METABOLIC EFFECTS: EVIDENCE FROM ANIMAL MODELS.

Authors:  Jonathan Jun; Vsevolod Y Polotsky
Journal:  Sleep Med Clin       Date:  2007-06

8.  Inflammation status of rabbit carotid artery model endothelium during intermittent hypoxia exposure and its relationship with leptin.

Authors:  Jing Feng; Bao-yuan Chen; Lin-yang Cui; Bao-li Wang; Chun-xia Liu; Pan-feng Chen; Mei-nan Guo; Li-xia Dong; Shuo Li
Journal:  Sleep Breath       Date:  2009-03-17       Impact factor: 2.816

Review 9.  Treatment alternatives for sleep-disordered breathing in the pediatric population.

Authors:  Ann C Halbower; Brian M McGinley; Philip L Smith
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

10.  Obstructive sleep apnea as a risk factor for type 2 diabetes.

Authors:  Nader Botros; John Concato; Vahid Mohsenin; Bernardo Selim; Kervin Doctor; Henry Klar Yaggi
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.